Stockscreener 앱 받기
2.80
0.36%
0.010
전일 마감가:
$2.79
열려 있는:
$2.77
하루 거래량:
10,980
Relative Volume:
0.81
시가총액:
$25.63M
수익:
-
순이익/손실:
$-23.87M
주가수익비율:
-0.1423
EPS:
-19.67
순현금흐름:
$-47.63M
1주 성능:
+11.33%
1개월 성능:
+11.55%
6개월 성능:
-16.10%
1년 성능:
-43.32%
1일 변동 폭
$2.75
$2.85
1주일 범위
$2.45
$3.25
52주 변동 폭
$2.30
$4.94
폴리피드 Stock (PYPD) Company Profile
PYPD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
2.80 | 25.63M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.85 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.16 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.26 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.69 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.55 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - Defense World
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - GlobeNewswire
PolyPid Q1 2025 Earnings Preview: Surgical Outcomes Biopharma Reports May 14 - Stock Titan
Reviewing Baxter International (NYSE:BAX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewswire
PolyPid to Reveal Next-Gen Surgical Innovation Pipeline at Elite Citizens Life Sciences Conference - Stock Titan
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 25.9% - Defense World
What is HC Wainwright’s Estimate for PolyPid Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for PolyPid Q1 Earnings? - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target - Investing.com Australia
PolyPid’s (PYPD) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target By Investing.com - Investing.com Canada
PolyPid stock touches 52-week low at $2.32 amid market challenges By Investing.com - Investing.com South Africa
PolyPid stock touches 52-week low at $2.32 amid market challenges - Investing.com Australia
Surgical Site Infections Clinical and Non-Clinical Studies, - openPR.com
Barclays Reaffirms Their Hold Rating on PolyPid (PYPD) - The Globe and Mail
Comparing Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks
PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - Yahoo
Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World
PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire
PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan
Polypid Ltd to Host Earnings Call - ACCESS Newswire
PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025 - The Globe and Mail
PolyPid Ltd. Earnings Call Highlights Promising Prospects - TipRanks
PolyPid Ltd. (NASDAQ:PYPD) Q4 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Positive Trial Progress and Financial Outlook - TipRanks
PolyPid targets SHIELD II trial completion with top-line results in Q2 2025 - MSN
PolyPid Updates: New Board Appointment and SHIELD II Trial Progress - TipRanks
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - The Manila Times
PolyPid's Phase 3 Trial Nears Completion: Key Financial Updates Reveal Path to Critical Q2 2025 Results - StockTitan
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
Head-To-Head Contrast: PolyPid (NASDAQ:PYPD) versus OraSure Technologies (NASDAQ:OSUR) - Defense World
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Surgical Outcomes Pioneer PolyPid Takes Center Stage at Major Healthcare Conference - StockTitan
PolyPid Ltd. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
PolyPid to Report Fourth Quarter and Full-Year 2024 - GlobeNewswire
Major Surgical Innovation Updates Expected: PolyPid Sets Critical Q4 Earnings Date - StockTitan
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
0.04%
자본화:
|
볼륨(24시간):